

*Supplementary Material*

Lacey W. Heinsberg, PhD, RN\*; Alysa Pomer, PhD;  
 Brian E. Cade, PhD; Jenna C. Carlson, PhD;  
 Take Naseri, MBBS, MPH; Muagututia Sefuiva Reupena, MS;  
 Satupa'itea Viali, MBChB, MPH; Daniel E. Weeks, PhD;  
 Stephen T. McGarvey, PhD, MPH;  
 Susan Redline, MD; Nicola L. Hawley, PhD

\*Corresponding author  
 Department of Human Genetics  
 School of Public Health  
 University of Pittsburgh  
 E-mail: law145@pitt.edu

**TABLE OF CONTENTS**

<b>Table/Figure/Section</b>	<b>Title</b>	<b>Page</b>
<a href="#">Abstract</a>	<i>Translated Abstract (Samoan)</i>	2
<a href="#">Methods S1</a>	<i>Expanded methods: WatchPAT data cleaning and quality control</i>	3
<a href="#">Code S1</a>	R code used to adjust for non-representational sampling and sample enrichment for the <i>CREBRF</i> obesity-risk allele.	4
<a href="#">Table S1</a>	Comparison of sample characteristics between overall sample and subset with WatchPAT data.	6
<a href="#">Table S2</a>	Sleep apnea categories by AHI 3%, AHI 4%, and ODI 4% across supine/non-supine positions and REM and non-REM sleep cycles.	7
<a href="#">Table S3</a>	Comparison of observed sample sleep apnea category frequencies and <i>CREBRF</i> -adjusted prevalence estimates.	8
<a href="#">Table S4</a>	Percent time spent <90% oxygen saturation, broken down by sleep apnea category.	9
<a href="#">Figure S1</a>	Sina with violin plots of sleep apnea measures by categorical participant characteristics.	10
<a href="#">Figure S2</a>	Sina with violin plots of sleep apnea measures by additional sleep environmental factors.	12
<a href="#">Figure S3</a>	Rain cloud plots describing sleep apnea measures more detailed age group and sex.	13
<a href="#">Figure S4</a>	Scatterplots of sleep apnea measures by continuous level participant characteristics.	14
<a href="#">Table S5</a>	Results of linear regression examining associations of square root transformed sleep apnea measures with <i>CRBERF</i> genotype while controlling for age and sex (Table S3a), <i>CREBRF</i> genotype while controlling for age, sex, and BMI (Table S3b), and <i>CREBRF</i> genotype while controlling for age, sex, and T2DM (Table S3c).	15
<a href="#">Figure S5</a>	Mosaic plot depicting the proportional distribution of sleep apnea categories by categorical BMI and sex.	16
<a href="#">Figure S6</a>	Mosaic plot depicting the proportional distribution of sleep apnea categories by categorical BMI and categorical age.	17
<a href="#">Figure S7</a>	Mosaic plot depicting the proportional distribution of sleep apnea categories by categorical age and sex.	18
<a href="#">Figure S8</a>	Mosaic plot depicting the proportional distribution of sleep apnea categories by <i>CREBRF</i> rs373863828 genotype and sex.	19

**Translated Abstract**

*A practice of our research group is to make an abstract that has been translated to Samoan available. At this time, only English language text is allowed by medRxiv. A Samoan translation is available upon request from [law145@pitt.edu](mailto:law145@pitt.edu).*

## SAMOA WATCHPAT

**Methods S1.** WatchPAT data cleaning and quality control: Data collection was attempted in 391 participants. Data were loaded from the WatchPAT device to a secure project computer and transferred to Brigham and Women's Hospital in Boston, USA via secure file transfer daily. Studies were initially scored using the device's automated zzzPAT software, editing events and sleep stages using an approach described by Zhang et al.<sup>1</sup> The algorithm was initially used to detect events associated with 4% desaturation criteria and then manually annotated such that events in non-REM sleep that were not accompanied by both a reciprocal decrease in the peripheral arterial tonometry signal and increase in heart rate were deleted. The AHI 3% was then calculated by retaining events that were identified to have a greater than or equal to 3% desaturation and less than a 4% desaturation and accompanied by both reciprocal peripheral arterial tonometry and heart rate changes. Any event that occurred during a position change was deleted. Sleep stages were automatically analyzed and edited if they did not show stage-specific patterns of heart rate, oxygen saturation, and peripheral arterial amplitude. Studies required a minimal of 3.7 hours of data on the oximetry and peripheral artery tonometry channels to be included. Post-QC, 330 participants were included for analyses.

## SAMOA WATCHPAT

**Code S1.** R code used to adjust for non-representational sampling and sample enrichment for the *CREBRF* obesity-risk allele.

```
# (1) Calculate expected genotype frequencies in the general population
# assuming a MAF p = 0.259
p <- 0.259
q <- 1 - p

freq_GG <- q^2
freq_AG <- 2 * p * q
freq_AA <- p^2

freq_GG

## [1] 0.549081

freq_AG

## [1] 0.383838

freq_AA

## [1] 0.067081

# (2) Calculate observed genotype frequencies in the sample
# 2a. Calculate the total number of participants of each genotype
total_GG <- sum(df$genotype_code == "GG")
total_AG <- sum(df$genotype_code == "AG")
total_AA <- sum(df$genotype_code == "AA")

total_GG

## [1] 145

total_AG

## [1] 139

total_AA

## [1] 46

# 2b. Calculate the frequency by dividing genotype-specific counts by total
# participant count (n=330)
freq_GG_observed <- total_GG/dim(df)[1]
freq_AG_observed <- total_AG/dim(df)[1]
freq_AA_observed <- total_AA/dim(df)[1]

freq_GG_observed

## [1] 0.4393939

freq_AG_observed

## [1] 0.4212121

freq_AA_observed

## [1] 0.1393939

# (3) Calculate weights for each genotype in our sample by dividing the
# expected (population) genotype frequency with the observed (sample) genotype
# frequency 3a. Calculate weights
weight_GG <- freq_GG/freq_GG_observed
weight_AG <- freq_AG/freq_AG_observed
weight_AA <- freq_AA/freq_AA_observed

weight_GG
```

## SAMOA WATCHPAT

```
## [1] 1.249633
```

```
weight_AG
```

```
## [1] 0.9112701
```

```
weight_AA
```

```
## [1] 0.4812333
```

```
# 3b. Add the weight variable to data frame
```

```
df <- df %>%
```

```
  mutate(weight = case_when(genotype_code == "GG" ~ weight_GG, genotype_code ==  
    "AG" ~ weight_AG, genotype_code == "AA" ~ weight_AA))
```

```
# (4) Adjust counts of the categorical AHI variable (cahi_3p) based on the step 3 weights
```

```
counts <- df %>%
```

```
  group_by(cahi_3p) %>%
```

```
  summarise(weighted_count = sum(weight), raw_count = n()) %>%
```

```
  ungroup
```

```
counts
```

```
## # A tibble: 4 × 2
```

```
##   cahi_3p weighted_count raw_count
```

```
##   <fct>         <dbl>     <int>
```

```
## 1 None           40.3         40
```

```
## 2 Mild           112.         109
```

```
## 3 Moderate       116.         114
```

```
## 4 Severe         61.7         67
```

# SAMOA WATCHPAT

**Table S1.** Comparison of sample characteristics between overall sample and subset with WatchPAT data.

Characteristic	Overall (n = 519)	Subset (n = 330)	p-value <sup>4</sup>
Age (years) <sup>1</sup>	52.2 (10.0)	52.0 (9.9)	0.776
Sex <sup>2</sup>			
<i>Male</i>	233 (44.9)	154 (46.7)	0.613
<i>Female</i>	286 (55.1)	176 (53.3)	
BMI (kg/m <sup>2</sup> ) <sup>1</sup>	35.8 (7.7)	35.5 (7.5)	0.579
<i>Missing</i>	16	1	
Abdominal-hip ratio <sup>1</sup>	0.98 (0.07)	0.98 (0.07)	0.999
<i>Missing</i>	16	2	
Type 2 Diabetes <sup>2</sup>			
<i>None</i>	61 (12.1)	40 (12.2)	0.999
<i>Pre-diabetes</i>	259 (51.5)	169 (51.5)	
<i>Diabetes</i>	183 (36.4)	119 (36.3)	
<i>Missing</i>	16	2	
Hypertension <sup>2</sup>			
<i>No</i>	324 (64.9)	215 (66.6)	0.630
<i>Yes</i>	175 (35.1)	108 (33.4)	
<i>Missing</i>	20	7	
Asthma <sup>2</sup>			
<i>No</i>	494 (95.6)	316 (95.8)	0.886
<i>Yes</i>	23 (4.4)	14 (4.2)	
<i>Missing</i>	2	0	
CREBRF rs373863828 genotype <sup>2</sup>			
<i>GG</i>	224 (43.2)	145 (43.9)	0.254
<i>AG</i>	201 (38.7)	139 (42.1)	
<i>AA</i>	94 (18.1)	46 (13.9)	
Census Region <sup>2</sup>			
<i>AUA</i>	116 (22.4)	68 (20.6)	0.753
<i>NWU</i>	221 (42.6)	139 (42.1)	
<i>ROU</i>	182 (35.0)	123 (37.3)	
Education (years) <sup>1</sup>	11.2 (2.7)	11.3 (2.9)	0.610
<i>Missing</i>	1	0	
Relationship Status <sup>2</sup>			
<i>Not partnered</i>	95 (18.3)	57 (17.3)	0.693
<i>Partnered</i>	423 (81.7)	273 (82.7)	
<i>Missing</i>	1	0	
Alcohol <sup>2</sup>			
<i>No</i>	478 (92.1)	305 (92.4)	0.864
<i>Yes</i>	41 (7.9)	25 (7.6)	
Smoking <sup>2</sup>			
<i>No</i>	320 (61.8)	207 (62.9)	0.738
<i>Yes</i>	198 (38.2)	122 (37.1)	
<i>Missing</i>	1	1	
Material Lifestyle Score (no. household assets) <sup>1</sup>	8.0 (4.0)	8.0 (4.1)	0.999
<i>Missing</i>	3	2	
Accelerometer-measured physical activity (minutes/day) <sup>3</sup>	73.0 (82.7)	75.3 (88.6)	0.497
<i>Missing</i>	87	39	

<sup>1</sup>mean (SD); <sup>2</sup>n (%); <sup>3</sup>median (IQR); <sup>4</sup>Statistical testing: T-test (variables with superscript <sup>1</sup>), chi-square test (variables with superscript <sup>2</sup>), or Mann-Whitney U Test (variables with superscript <sup>3</sup>); AUA = Apia Urban Area; NWU = Northwest 'Upolu; ROU = Rest of 'Upolu; Hypertension, defined as an average value  $\geq 140/90$  mmHg and/or current hypertension medication use; Diabetes, based on Hemoglobin A1c values or current use of diabetes medication; Asthma, self-report history of asthma diagnosis; Smoking, defined based on self-report of current use of cigarettes, cigars, or pipes; Alcohol, defined based on self-report of consumption of alcohol in the past 12 months; Moderate-vigorous physical activity, average minutes/day measured using accelerometer.

SAMOA WATCHPAT

**Table S2.** Sleep apnea categories by AHI 3%, AHI 4%, and ODI 4% across supine/non-supine positions and REM and non-REM sleep cycles, n (%).

Supine	All (n=316)			Male (n=152)			Female (n=164)		
	AHI 3%	AHI 4%	ODI 4%	AHI 3%	AHI 4%	ODI 4%	AHI 3%	AHI 4%	ODI 4%
<b>All categories</b>									
<i>None/minimal sleep apnea (&lt;5 events/hr)</i>	33 (10.4)	96 (30.4)	87 (27.5)	10 (6.6)	37 (24.3)	33 (21.7)	23 (14.0)	59 (36.0)	54 (32.9)
<i>Mild (5 to &lt;15 events/hr)</i>	64 (20.3)	89 (28.2)	91 (28.8)	25 (16.4)	38 (25.0)	40 (26.3)	39 (23.8)	51 (31.1)	51 (31.1)
<i>Moderate (15 to&lt;30 events/hr)</i>	92 (29.1)	75 (23.7)	82 (25.9)	36 (26.7)	36 (23.7)	38 (25.0)	56 (34.1)	39 (23.8)	44 (26.8)
<i>Severe (≥30)</i>	127 (40.2)	56 (17.7)	56 (17.7)	81 (53.3)	41 (27.0)	41 (27.0)	46 (27.9)	15 (9.1)	15 (9.1)
<b>Clinical categories</b>									
<i>Potentially actionable (≥5 events/hr)</i>	283 (89.6)	220 (69.6)	229 (72.4)	142 (96.4)	115 (75.7)	119 (78.3)	141 (85.8)	105 (64.0)	110 (67.0)
<i>Clinically actionable (≥15 events/hr)</i>	219 (69.3)	131 (41.4)	138 (43.6)	117 (80.0)	77 (50.7)	79 (52.0)	102 (62.0)	54 (32.9)	59 (35.9)
Non-supine	All (n=315)			Male (n=148)			Female (n=167)		
	AHI 3%	AHI 4%	ODI 4%	AHI 3%	AHI 4%	ODI 4%	AHI 3%	AHI 4%	ODI 4%
<b>All categories</b>									
<i>None/minimal sleep apnea (&lt;5 events/hr)</i>	66 (21.0)	153 (48.6)	135 (42.9)	26 (17.6)	74 (50.0)	69 (46.6)	40 (24.0)	79 (47.3)	66 (39.5)
<i>Mild (5 to &lt;15 events/hr)</i>	82 (26.0)	97 (30.8)	104 (33.0)	37 (25.0)	37 (25.0)	36 (24.3)	45 (26.9)	60 (35.9)	68 (40.7)
<i>Moderate (15 to&lt;30 events/hr)</i>	84 (26.7)	38 (12.1)	42 (13.3)	40 (27.0)	21 (14.2)	23 (15.5)	44 (26.3)	17 (10.2)	19 (11.4)
<i>Severe (≥30)</i>	83 (26.3)	27 (8.6)	34 (10.8)	45 (30.4)	16 (10.8)	20 (13.5)	38 (22.8)	11 (6.6)	14 (8.4)
<b>Clinical categories</b>									
<i>Potentially actionable (≥5 events/hr)</i>	249 (79.0)	162 (51.5)	180 (57.1)	122 (82.4)	74 (50.0)	79 (53.3)	127 (76.0)	88 (52.7)	101 (60.5)
<i>Clinically actionable (≥15 events/hr)</i>	167 (53.0)	65 (20.7)	76 (24.1)	85 (57.4)	37 (25.0)	43 (29.0)	82 (49.1)	28 (16.8)	33 (19.8)
REM	All (n=303)			Male (n=138)			Female (n=165)		
	AHI 3%	AHI 4%	ODI 4%	AHI 3%	AHI 4%	ODI 4%	AHI 3%	AHI 4%	ODI 4%
<b>All categories</b>									
<i>None/minimal sleep apnea (&lt;5 events/hr)</i>	20 (6.6)	58 (19.1)		8 (5.8)	28 (20.3)		12 (7.3)	30 (18.2)	
<i>Mild (5 to &lt;15 events/hr)</i>	62 (20.5)	75 (24.8)		29 (21.0)	31 (22.5)		33 (20.0)	44 (26.7)	
<i>Moderate (15 to&lt;30 events/hr)</i>	87 (28.7)	76 (25.1)		41 (29.7)	34 (24.6)		46 (27.9)	42 (25.5)	
<i>Severe (≥30)</i>	134 (44.2)	94 (31.0)		60 (43.5)	45 (32.6)		74 (44.8)	49 (29.7)	
<b>Clinical categories</b>									
<i>Potentially actionable (≥5 events/hr)</i>	283 (93.4)	245 (80.9)		130 (94.2)	110 (79.7)		153 (92.7)	135 (81.9)	
<i>Clinically actionable (≥15 events/hr)</i>	221 (72.9)	170 (56.1)		101 (73.2)	79 (57.2)		120 (72.7)	91 (55.2)	
Non-REM	All (n=303)			Male (n=138)			Female (n=165)		
	AHI 3%	AHI 4%	ODI 4%	AHI 3%	AHI 4%	ODI 4%	AHI 3%	AHI 4%	ODI 4%
<b>All categories</b>									
<i>None/minimal sleep apnea (&lt;5 events/hr)</i>	68 (22.4)	133 (43.9)		25 (18.1)	50 (36.2)		43 (26.1)	83 (50.3)	
<i>Mild (5 to &lt;15 events/hr)</i>	113 (37.3)	99 (32.7)		44 (31.9)	42 (30.4)		69 (41.8)	57 (34.5)	
<i>Moderate (15 to&lt;30 events/hr)</i>	78 (25.7)	50 (16.5)		42 (30.4)	33 (23.9)		36 (21.8)	17 (10.3)	
<i>Severe (≥30)</i>	44 (14.5)	21 (6.9)		27 (19.6)	13 (9.4)		17 (10.3)	8 (4.8)	
<b>Clinical categories</b>									
<i>Potentially actionable (≥5 events/hr)</i>	235 (77.5)	170 (56.1)		113 (81.9)	88 (63.7)		122 (73.9)	82 (49.6)	
<i>Clinically actionable (≥15 events/hr)</i>	122 (40.2)	71 (23.4)		69 (50.0)	46 (33.3)		53 (32.1)	25 (15.1)	

AHI, apnea hypopnea index; ODI, oxygen desaturation index; REM, rapid eye movement.

SAMOA WATCHPAT

**Table S3.** Comparison of observed sample sleep apnea category frequencies and *CREBRF*-adjusted prevalence estimates.

<b>Categorical AHI 3% (events/hr)</b>	<b>Observed categorical counts, n (%)</b>	<b><i>CREBRF</i>-adjusted categorical counts, n (%)<sup>1</sup></b>
<b><i>All categories</i></b>		
<i>None/minimal sleep apnea (&lt;5 events/hr)</i>	40 (12.1)	40.3 (12.2)
<i>Mild (5 to &lt;15 events/hr)</i>	109 (33.0)	112 (33.9)
<i>Moderate (15 to &lt;30 events/hr)</i>	114 (34.6)	116 (35.2)
<i>Severe (≥30)</i>	67 (20.3)	61.7 (18.7)
<b><i>Clinical categories</i></b>		
<i>Potentially actionable (≥5 events/hr)</i>	290 (87.9)	289.7 (87.8)
<i>Clinically actionable (≥15 events/hr)</i>	181 (54.9)	177.7 (53.9)
<b>Categorical AHI 4% (events/hr)</b>		
<b>Observed categorical counts, n (%)</b>		
<b><i>CREBRF</i>-adjusted categorical counts, n (%)<sup>1</sup></b>		
<b><i>All categories</i></b>		
<i>None/minimal sleep apnea (&lt;5 events/hr)</i>	104 (31.5)	108 (32.7)
<i>Mild (5 to &lt;15 events/hr)</i>	122 (37.0)	123 (37.3)
<i>Moderate (15 to &lt;30 events/hr)</i>	69 (20.9)	68.8 (20.8)
<i>Severe (≥30)</i>	35 (10.6)	30.2 (9.2)
<b><i>Clinical categories</i></b>		
<i>Potentially actionable (≥5 events/hr)</i>	226 (68.5)	222 (67.3)
<i>Clinically actionable (≥15 events/hr)</i>	104 (31.5)	99 (30.0)
<b>Categorical ODI 4% (events/hr)</b>		
<b>Observed categorical counts, n (%)</b>		
<b><i>CREBRF</i>-adjusted categorical counts, n (%)<sup>1</sup></b>		
<b><i>All categories</i></b>		
<i>None/minimal sleep apnea (&lt;5 events/hr)</i>	95 (28.8)	97.8 (29.6)
<i>Mild (5 to &lt;15 events/hr)</i>	121 (36.7)	123.1 (37.3)
<i>Moderate (15 to &lt;30 events/hr)</i>	74 (22.4)	73.6 (22.3)
<i>Severe (≥30)</i>	40 (12.1)	35.5 (10.8)
<b><i>Clinical categories</i></b>		
<i>Potentially actionable (≥5 events/hr)</i>	235 (71.2)	232.2 (70.4)
<i>Clinically actionable (≥15 events/hr)</i>	114 (34.5)	109.1 (33.1)

n=330. <sup>1</sup>To estimate sleep apnea category prevalence that adjusts for sample ascertainment bias (i.e., *CREBRF* obesity-risk allele oversampling) and is therefore likely more generalizable to the population, we used post-stratification calibration as shown in Code S1. This approach was similar to inverse probability weighting in that each individual observation was weighted by their chance of being in the sample. Specifically, we estimated genotype-specific weights as the observed/expected genotype frequency and then sleep apnea category counts were adjusted based on genotype. Observed sample genotype frequencies of GG=0.439, AG=0.421, and AA=0.139; expected genotype frequencies (based on population minor allele frequency of 0.259) of GG=0.549, AG=0.383, and AA=0.067; genotype specific weights of GG=1.251, AG=0.910, AA=0.482.



SAMOA WATCHPAT


**Table S4.** Categorical percent time spent <90% oxygen saturation, broken down by sleep apnea category.

<b>All participants (n=330)</b>		<b>Sleep apnea category</b>			
<b>Hypoxia category<sup>1</sup></b>		None (n=40)	Mild (n=109)	Moderate (n=114)	Severe (n=67)
0%	None	31 (77.5)	46 (42.2)	9 (7.9)	0
>0 to <5%	Light	9 (22.5)	63 (57.8)	95 (83.3)	34 (50.7)
5% to <10%	Mild	0	0	8 (7.0)	8 (11.9)
10% to <25%	Moderate	0	0	2 (1.8)	19 (28.4)
≥25%	Severe	0	0	0	6 (9.0)
<b>Male participants (n=154)</b>		<b>Sleep apnea category</b>			
<b>Hypoxia category<sup>1</sup></b>		None (n=18)	Mild (n=41)	Moderate (n=54)	Severe (n=41)
0%	None	12 (66.7)	17 (41.5)	7 (13.0)	0
>0 to <5%	Light	6 (33.3)	24 (58.5)	44 (81.5)	16 (39.0)
5% to <10%	Mild	0	0	3 (5.6)	4 (9.8)
10% to <25%	Moderate	0	0	0	18 (43.9)
≥25%	Severe	0	0	0	3 (7.3)
<b>Female participants (n=176)</b>		<b>Sleep apnea category</b>			
<b>Hypoxia category<sup>1</sup></b>		None (n=22)	Mild (n=68)	Moderate (n=60)	Severe (n=26)
0%	None	19 (86.4)	29 (42.6)	2 (3.3)	0
>0 to <5%	Light	3 (13.6)	39 (57.4)	51 (85.0)	18 (69.2)
5% to <10%	Mild	0	0	5 (8.3)	4 (15.4)
10% to <25%	Moderate	0	0	2 (3.3)	1 (3.8)
≥25%	Severe	0	0	0	3 (11.5)

<sup>1</sup>Based on % time spent at <90% oxygen saturation

# SAMOA WATCHPAT

**Figure S1.** Sina with violin plots of sleep apnea measures by categorical participant characteristics.




AHI = apnea hypopnea index; ODI = oxygen desaturation index; Age (years); BMI (kg/m<sup>2</sup>), 'Normal' = 18-25.99 kg/m<sup>2</sup>, Overweight = 26-32 kg/m<sup>2</sup>, Obesity = >32 kg/m<sup>2</sup>; Hypertension, defined as an average value  $\geq 140/90$  mmHg and/or current hypertension medication use; Diabetes, Type 2 diabetes status was determined based on any of the following: current use of diabetes medication,

## SAMOA WATCHPAT

Hemoglobin A1c (HbA1c) (5.7-6.4%, pre-diabetes; >6.4%, diabetes), fasting blood glucose (FBG; 100-125, pre-diabetes;  $\geq 126$ , diabetes), and/or oral glucose tolerance testing based on the American Diabetes Association criteria; Asthma, self-report history of asthma diagnosis; Smoking, defined based on self-report of current use of cigarettes, cigars, or pipes; Alcohol, defined based on self-report of consumption of alcohol in the past 12 months; Not partnered = never married, separated, divorced, or widowed; Partnered = currently married or cohabitating; *CREBRF* genotype corresponds to rs373863828, minor allele = A; AUA = Apia Urban Area; NWU = Northwest 'Upolu; ROU = Rest of 'Upolu. Black horizontal line depicts subgroup median; green horizontal line indicates p-value < 0.05. Wilcox test used for binary variables, Kruskal-Wallis test used for variables with more than two levels.

SAMOA WATCHPAT


Figure S2. Sina with violin plots of sleep apnea measures by additional sleep environmental factors.



AHI = apnea hypopnea index; ODI = oxygen desaturation index; Room sharing = number of people sharing a room the night of the WatchPAT assessment, >3 category ranges from 3-9; Bed sharing = number of people sharing the sleep surface the night of the WatchPAT assessment, >3 category ranges from 3-9; Sleep surface = sleep surface the night of the WatchPAT assessment, other category includes carpet/floor/blanket/mat on sofa/sofa. Black horizontal line depicts subgroup median. Wilcox test used for binary variables, Kruskal-Wallis test used for variables with more than two levels.

# SAMOA WATCHPAT


Figure S3. Rain cloud plots describing sleep apnea measures more detailed age group and sex.



AHI = apnea hypopnea index; ODI = oxygen desaturation index. Black horizontal line depicts subgroup median.

SAMOA WATCHPAT

Figure S4. Scatterplots of sleep apnea measures by continuous level participant characteristics.



AHI = apnea hypopnea index; ODI = oxygen desaturation index; Age (years); BMI ( $\text{kg}/\text{m}^2$ ); Physical activity, moderate-vigorous physical activity (min/day) measured using accelerometer; Household assets as a measure of material lifestyle score/socioeconomic position. R, Spearman correlation coefficient; p-value evaluated a null hypothesis of  $R=0$ ; blue line indicates fitted linear regression line; gray shading indicates 95% confidence interval for regression line.

SAMOA WATCHPAT

**Table S5.** Results of linear regression examining associations of square root transformed sleep apnea measures with *CRBRF* genotype while controlling for age and sex (Table S3a), *CRBRF* genotype while controlling for age, sex, and BMI (Table S3b), and *CRBRF* genotype while controlling for age, sex, and T2DM (Table S3c).

Table S3a. No covariates (n=330)												
Term	$\hat{\beta}$	AHI 3%			$\hat{\beta}$	AHI 4%			$\hat{\beta}$	ODI 4%		
		2.5th	97.5th	p		2.5th	97.5th	p		2.5th	97.5th	p
<i>CRBRF</i> genotype	0.364	0.116	0.611	<u>0.004</u>	0.394	0.137	0.652	<u>0.003</u>	0.396	0.137	0.656	<u>0.003</u>
Age	0.024	0.007	0.042	<u>0.007</u>	0.022	0.004	0.040	<u>0.020</u>	0.022	0.003	0.040	<u>0.022</u>
Sex, Female (Ref=Male)	-0.458	-0.806	-0.110	<u>0.013</u>	-0.497	-0.858	-0.135	<u>0.008</u>	-0.543	-0.908	-0.178	<u>0.004</u>
Table S3b. Controlling for BMI (n=329)												
Term	$\hat{\beta}$	AHI 3%			$\hat{\beta}$	AHI 4%			$\hat{\beta}$	ODI 4%		
		2.5th	97.5th	p		2.5th	97.5th	p		2.5th	97.5th	p
<i>CRBRF</i> genotype	0.085	-0.127	0.296	0.433	0.094	-0.122	0.310	0.394	0.096	-0.123	0.314	0.391
BMI	0.127	0.106	0.148	<u>2.03E-27</u>	0.138	0.116	0.159	<u>3.44E-30</u>	0.138	0.116	0.159	<u>1.09E-29</u>
Age	0.036	0.021	0.050	<u>3.49E-06</u>	0.034	0.019	0.049	<u>1.38E-05</u>	0.034	0.018	0.049	<u>1.97E-05</u>
Sex	-0.966	-1.269	-0.664	<u>1.27E-09</u>	-1.052	-1.361	-0.743	<u>1.12E-10</u>	-1.099	-1.412	-0.786	<u>3.05E-11</u>
Table S3c. Controlling for T2DM (n=328)												
Term	$\hat{\beta}$	AHI 3%			$\hat{\beta}$	AHI 4%			$\hat{\beta}$	ODI 4%		
		2.5th	97.5th	p		2.5th	97.5th	p		2.5th	97.5th	p
<i>CRBRF</i> genotype	0.397	0.144	0.650	<u>0.002</u>	0.435	0.172	0.698	<u>0.028</u>	0.437	0.172	0.702	<u>0.001</u>
Pre-T2DM (Ref=No diabetes)	0.411	-0.148	0.969	0.151	0.418	-0.163	0.998	0.159	0.418	-0.168	1.003	0.163
T2DM (Ref=No diabetes)	0.399	-0.201	0.999	0.193	0.456	-0.167	1.079	0.152	0.457	-0.171	1.086	0.155
Age	0.023	0.004	0.411	<u>0.016</u>	0.020	0.001	0.039	<u>0.045</u>	0.019	8.45E-05	0.386	<u>0.049</u>
Sex	-0.475	-0.826	-0.124	<u>0.008</u>	-0.522	-0.886	-0.157	<u>0.005</u>	-0.567	-0.935	-0.200	<u>0.003</u>

$\hat{\beta}$  = regression estimate for square root transformed dependent variable (sleep apnea measure).


2.5<sup>th</sup> = lower bound of 95% confidence interval for  $\hat{\beta}$ ; 97.5<sup>th</sup> = upper bound of 95% confidence interval for  $\hat{\beta}$ .

Underlined p-values indicate p<0.05.

*CRBRF* rs373863828 genotype modeled additively based on number of copies of minor allele; BMI = body mass index (kg/m<sup>2</sup>); Pre-T2DM = pre-type 2 diabetes; T2DM = type 2 diabetes.

SAMOA WATCHPAT

Figure S5. Mosaic plot depicting the proportional distribution of sleep apnea categories by categorical BMI and sex.




Category = AHI 3% categorized based on the number of events/hr: None (<5), Mild (5-14.9), Moderate (15-29.9), Severe ( $\geq 30$ ). BMI, body mass index categorized: Normal (18.5 to <26 kg/m<sup>2</sup>), Overweight (26 to 32 kg/m<sup>2</sup>), Obesity ( $\geq 32$  kg/m<sup>2</sup>). Sex: M = male, F = female. Plot interpretation: The size of the tile is proportional to the percentage of cases in that combination of levels; assuming the three variables of interest are independent, blue shading indicates more cases than expected while red shading indicates less cases than expected (e.g., within the severe category, we see a greater number of males than expected while in the none and mild categories, we see a lower number of males than expected, suggesting a compounding of effect of sex on categorical BMI).



SAMOA WATCHPAT


Figure S6. Mosaic plot depicting the proportional distribution of sleep apnea categories by categorical BMI and categorical age.



Category = AHI 3% categorized based on the number of events/hr: None (<5), Mild (5-14.9), Moderate (15-29.9), Severe (≥30). BMI, body mass index categorized: Normal (18.5 to <26 kg/m<sup>2</sup>), Overweight (26 to 32 kg/m<sup>2</sup>), Obesity (≥ 32 kg/m<sup>2</sup>). Age: A ≥ 50 years, B < 50 years. Plot interpretation: The size of the tile is proportional to the percentage of cases in that combination of levels; assuming the three variables of interest are independent, blue shading indicates more cases than expected while red shading indicates less cases than expected.

SAMOA WATCHPAT


Figure S7. Mosaic plot depicting the proportional distribution of sleep apnea categories by categorical age and sex.



Category = AHI 3% categorized based on the number of events/hr: None (<5), Mild (5-14.9), Moderate (15-29.9), Severe ( $\geq 30$ ). Age: A  $\geq 50$  years, B < 50 years. Sex: M = male, F = female. Plot interpretation: The size of the tile is proportional to the percentage of cases in that combination of levels; assuming the three variables of interest are independent, blue shading indicates more cases than expected while red shading indicates less cases than expected.

SAMOA WATCHPAT

**Figure S8.** Mosaic plot depicting the proportional distribution of sleep apnea categories by *CREBRF* rs373863828 genotype and sex.



Category = AHI 3% categorized based on the number of events/hr: None (<5), Mild (5-14.9), Moderate (15-29.9), Severe ( $\geq 30$ ). Sex: M = male, F = female. Plot interpretation: The size of the tile is proportional to the percentage of cases in that combination of levels; assuming the three variables of interest are independent, blue shading indicates more cases than expected while red shading indicates less cases than expected.

SAMOA WATCHPAT  
REFERENCES

1. Zhang Z, Sowho M, Otvos T, et al. A comparison of automated and manual sleep staging and respiratory event recognition in a portable sleep diagnostic device with in-lab sleep study. *J Clin Sleep Med.* 2020;16(4):563-573. doi:10.5664/jcsm.8278